| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Overexpression of the c-erbB-2 gene-encoded p185 has been reported in approximately 30% of human breast cancers and has been correlated with lymph node metastasis and poor prognosis in breast cancer patients. To investigate whether overexpression of p185 can enhance the metastatic potential of human breast cancer cells, we have introduced the human c-erbB-2 gene into the very low p185-expressing MDA-MB-435 human breast cancer cells and established 435.eB transfectants that express higher levels of p185. In this study, we compared the metastatic phenotypes of the parental MDA-MB-435 cells and the 435.eB transfectants. In vivo experimental metastasis assays in which we injected MDA-MB-435 parental cells or 435.eB transfectants into the tail veins of ICR-SCID mice demonstrated that mice injected with p185-overexpressing 435.eB transfectants formed significantly more metastatic tumors than the mice injected with parental and control cells. The changes in experimental metastatic potential in vivo were accompanied by increased invasiveness in vitro. In addition, the secretion of basement membrane-degradative enzymes, which is an important step in the invasion and metastasis process, was also increased in the p185-overexpressing 435.eB transfectants. These results indicated that p185 overexpression can enhance the metastatic potential of MDA-MB-435 human breast cancer cells. To investigate whether enhanced metastatic potential in the p185-overexpressing 435.eB transfectants was the result of increased cancer cell growth and transformation potential, we compared the growth rate, anchorage-independent growth ability, and tumorigenicity of the 435.eB transfectants with that of the parental cells. The transfectants and the parental cells all had similar growth rates and anchorage-independent growth abilities and demonstrated similar tumorigenic potential. These findings suggest that c-erbB-2 is a metastasis-promoting gene for breast cancers that is distinct from other tumor-promoting genes in that the c-erbB-2 gene can enhance the intrinsic metastatic potentials of MDA-MB-435 cells without increasing their transformation abilities.
1 This research was in part supported by Cancer Center Core Support Grant P30-CA16672 from the National Cancer Institute and Grant CA60488 (to D. Y.) from the National Cancer Institute. J. Y. was an awardee of the Rosalie B. Hite predoctoral fellowship.
2 To whom requests for reprints should be addressed, at the Department of Surgical Oncology, Box 107, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-3636; Fax: (713) 794-4830.
Received 7/31/96. Accepted 1/20/97.
This article has been cited by other articles:
![]() |
J. M. Park, M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and J. A. Berzofsky Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine Cancer Res., March 15, 2008; 68(6): 1979 - 1987. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Palmieri, J. L. Bronder, J. M. Herring, T. Yoneda, R. J. Weil, A. M. Stark, R. Kurek, E. Vega-Valle, L. Feigenbaum, D. Halverson, et al. Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain Cancer Res., May 1, 2007; 67(9): 4190 - 4198. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Meric-Bernstam and M.-C. Hung Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, M. Zhan, J. A.F. Hannay, P. Das, S. V. Bolshakov, D. Kotilingam, D. Yu, A. F. Lazar, R. E. Pollock, and D. Lev Wild-type p53 Inhibits Nuclear Factor-{kappa}B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis Mol. Cancer Res., November 1, 2006; 4(11): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry, and M.-C. Hung MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Mol. Cell. Biol., October 1, 2006; 26(19): 7269 - 7282. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tan, K.-H. Lan, J. Yao, C.-H. Lu, M. Sun, C. L. Neal, J. Lu, and D. Yu Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3-Blocking Peptide. Cancer Res., April 1, 2006; 66(7): 3764 - 3772. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Klos, S. L. Wyszomierski, M. Sun, M. Tan, X. Zhou, P. Li, W. Yang, G. Yin, W. N. Hittelman, and D. Yu ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells Cancer Res., February 15, 2006; 66(4): 2028 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Xue, F. Liang, R. Mahmood, M. Vuolo, J. Wyckoff, H. Qian, K.-L. Tsai, M. Kim, J. Locker, Z.-Y. Zhang, et al. ErbB3-Dependent Motility and Intravasation in Breast Cancer Metastasis Cancer Res., February 1, 2006; 66(3): 1418 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene J Natl Cancer Inst, November 2, 2005; 97(21): 1611 - 1615. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. U. Thompson, J. M. Chen, T. Li, K. Strasser-Weippl, and P. E. Goss Dietary Flaxseed Alters Tumor Biological Markers in Postmenopausal Breast Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3828 - 3835. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Park, M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J. C. Morris, and J. A. Berzofsky Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas J. Immunol., April 1, 2005; 174(7): 4228 - 4236. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tan, P. Li, K. S. Klos, J. Lu, K.-H. Lan, Y. Nagata, D. Fang, T. Jing, and D. Yu ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis Cancer Res., March 1, 2005; 65(5): 1858 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification Ann. Onc., March 1, 2005; 16(3): 359 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Pierson-Mullany and C. A. Lange Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2 Mol. Cell. Biol., December 15, 2004; 24(24): 10542 - 10557. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhou, M. Tan, V. Stone Hawthorne, K. S. Klos, K.-H. Lan, Y. Yang, W. Yang, T. L. Smith, D. Shi, and D. Yu Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers Clin. Cancer Res., October 15, 2004; 10(20): 6779 - 6788. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sellappan, R. Grijalva, X. Zhou, W. Yang, M. B. Eli, G. B. Mills, and D. Yu Lineage Infidelity of MDA-MB-435 Cells: Expression of Melanocyte Proteins in a Breast Cancer Cell Line Cancer Res., May 15, 2004; 64(10): 3479 - 3485. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Madhusudan, A. Tamir, N. Bates, E. Flanagan, M. E. Gore, D. P. J. Barton, P. Harper, M. Seckl, H. Thomas, N. R. Lemoine, et al. A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene Clin. Cancer Res., May 1, 2004; 10(9): 2986 - 2996. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Etges, D S Pinto Jr, L P Kowalski, F A Soares, and V C Araujo Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour J. Clin. Pathol., December 1, 2003; 56(12): 914 - 918. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry Clin. Cancer Res., September 1, 2003; 9(10): 3645 - 3652. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lee, W. Yang, K.-H. Lan, S. Sellappan, K. Klos, G. Hortobagyi, M.-C. Hung, and D. Yu Enhanced Sensitization to Taxol-induced Apoptosis by Herceptin Pretreatment in ErbB2-overexpressing Breast Cancer Cells Cancer Res., October 15, 2002; 62(20): 5703 - 5710. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ren and T. S. Schaefer ErbB-2 Activates Stat3alpha in a Src- and JAK2-dependent Manner J. Biol. Chem., October 4, 2002; 277(41): 38486 - 38493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Alhasan, O. Aranha, and F. H. Sarkar Genistein Elicits Pleiotropic Molecular Effects on Head and Neck Cancer Cells Clin. Cancer Res., December 1, 2001; 7(12): 4174 - 4181. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Suo, H. Yang, Q. Mei, E. Skovlund, J. Cui, and J. M. Nesland Type 1 Protein Tyrosine Kinases in Chinese Breast Carcinomas: A Clinicopathologic Study International Journal of Surgical Pathology, July 1, 2001; 9(3): 177 - 187. [Abstract] [PDF] |
||||
![]() |
N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, H. Tsai, and B. K. Seon Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin Clin. Cancer Res., March 1, 2001; 7(3): 524 - 532. [Abstract] [Full Text] |
||||
![]() |
H. Allgayer, R. Babic, K. U. Gruetzner, A. Tarabichi, F. W. Schildberg, and M. M. Heiss c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems J. Clin. Oncol., June 11, 2000; 18(11): 2201 - 2209. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, M. Bhuiyan, S. Alhasan, A. M. Senderowicz, and F. H. Sarkar Induction of Apoptosis and Inhibition of c-erbB-2 in Breast Cancer Cells by Flavopiridol Clin. Cancer Res., January 1, 2000; 6(1): 223 - 229. [Abstract] [Full Text] |
||||
![]() |
B. H. BRANDT, A. ROETGER, T. DITTMAR, G. NIKOLAI, M. SEELING, A. MERSCHJANN, J.-R. NOFER, G. DEHMER-MÖLLER, R. JUNKER, G. ASSMANN, et al. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells FASEB J, November 1, 1999; 13(14): 1939 - 1949. [Abstract] [Full Text] |
||||
![]() |
R. Worthylake, L. K. Opresko, and H. S. Wiley ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors J. Biol. Chem., March 26, 1999; 274(13): 8865 - 8874. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Roetger, A. Merschjann, T. Dittmar, C. Jackisch, A. Barnekow, and B. Brandt Selection of Potentially Metastatic Subpopulations Expressing c-erbB-2 from Breast Cancer Tissue by Use of an Extravasation Model Am. J. Pathol., December 1, 1998; 153(6): 1797 - 1806. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |